Leadership Changes At SOHM, Inc. (SHMN) to Strengthen Growth Strategies for Generic Drug Market and Gene Editing Platform Development

  • U.S.-based generic drug developer SOHM recently announced the addition of two leading officers — Dr. David Aguilar (Ph.D) as Chief Operating Officer and Dr. Krishna Bhat (MD, Ph.D, FACC) as Chief Medical Advisor
  • The new officers are expected to help direct SOHM’s global growth strategy as the company continues to develop and diversify its product offerings, which include a variety of mediums for administering antibiotics, analgesics, anti-inflammatory and anti-cold therapies, as well as vitamins
  • SOHM also recently announced an LOI to acquire a stem cell disruptive technology and related patents, which include the potential for someday treating damaged hearts via gene editing
  • The company’s global operation is primarily focused on emerging markets in Africa, Latin America, and Southeast Asia

Generic drug manufacturing and distributing innovator SOHM (OTC: SHMN) is strengthening its governing team with the addition of two experienced visionaries committed to helping the company’s growth in the pharmaceutical, nutraceutical, and cosmeceutical marketplace.

Dr. Krishna Bhat (MD, Ph.D, FACC), an experienced bioscientist and cardiologist, will bring his leadership skills to the company’s advisory board as its new Chief Medical Advisor, increasing his commitment beyond his involvement as a longtime shareholder, according to an announcement Aug. 24.

“Dr. Bhat brings valuable experience and expertise in the field of cardiology, which will support our planned acquisition of ABBIE Technology and its innovative patents, clinical trials, diagnostic kits and cardiac treatments,” SOHM president and CEO Baron Night stated in the news release (https://ibn.fm/ZNXX2). “Dr. Bhat is a renowned Clinical and Interventional Cardiologist who has authored over 16 medical scientific publications. We look forward to benefiting from his insights and guidance for our current and future pipelines.”

Earlier in August, SOHM signed a letter of intent to acquire “ABBIE” (A Binding Based Integrating Enzyme) stem cell disruptive technology and patents from CGA Intellectual Holdings Inc. to create novel products and solutions in the regenerative medicine and cosmeceutical industries, with initial development focused on “optimization of targeting and understanding limitations of the ‘payload’ size that can be utilized to deliver the gene(s) of interest” (https://ibn.fm/25YWT).

The ABBIE platform is still in early stages of research and development, but it has already shown promising results through gene editing in animal and human cells in vitro and is expected to provide significant solutions for cardiac patients by offering cell therapies to repair damaged hearts (https://ibn.fm/2cR9S).

SOHM also recently announced the appointment of Dr. David Aguilar (Ph.D) as Chief Operating Officer to direct the company’s sustainability, stability, growth and new developments at its uppermost level, drawing on his 22 years of experience in the pharmaceutical industry working with clinical and regulatory needs for preclinical and IND filings of allogeneic cell-based therapies.

“We are delighted and fortunate to have someone with Dr. David Aguilar’s talent, business acumen and deep institutional knowledge of SOHM, Inc. oversee these functions and manage our global businesses,” Night stated in the Aug. 8 announcement (https://ibn.fm/cCzUz).

SOHM is headquartered in California and exports its products around the world, focusing on emerging markets in Africa, Latin America and Southeast Asia. The company uses manufacturing alliances in India and strategic alliances with U.S. manufacturing facilities to develop its product line, which includes antibiotics, analgesics, anti-inflammatory and anti-cold therapies, and vitamins.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050